Minervax ApS
- Country
- 🇩🇰Denmark
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.minervax.com
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women
- Conditions
- Streptococcus Agalactiae InfectionNeonatal SepsisPneumoniaMeningitisNeonatal InfectionGram-Positive Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfections
- Interventions
- Biological: GBS-NN/NN2 vaccine
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Minervax ApS
- Target Recruit Count
- 338
- Registration Number
- NCT06592586
- Locations
- 🇩🇰
Aarhus Universitetshospital, Aarhus N, Midtjylland, Denmark
🇩🇰Sygehus Lillebælt - Kolding Sygehus, Kolding, Syddanmark, Denmark
🇿🇦Sefako Makgatho Health Sciences University, Medunsa Clinical Research Unit (MeCRU), Ga-Rankuwa, Gauteng, South Africa
GBS-NN/NN2 (50 µg of Each Fusion Protein [GBS-NN and GBS-NN2] in Combination With 500 µg Aluminum as Alhydrogel®) Given With and Without the Tdap Vaccine in Healthy Non-pregnant Women 18 to 49 Years of Age
- Conditions
- Streptococcus Agalactiae Infection
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Minervax ApS
- Target Recruit Count
- 564
- Registration Number
- NCT06494475
A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers
- Conditions
- Group B Streptococcus Infection
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Minervax ApS
- Target Recruit Count
- 55
- Registration Number
- NCT06280157
- Locations
- 🇬🇧
Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, Pentrebach Merthyr Tydfil CF48 4DR, United Kingdom
Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants
- Conditions
- Group B Streptococcal Infections
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Minervax ApS
- Target Recruit Count
- 90
- Registration Number
- NCT05782179
- Locations
- 🇧🇪
University Hospital Ghent - Centrum voor Vaccinologie (CEVAC) department, Ghent, Belgium
Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women
- Conditions
- Group B Streptococcal Infection
- Interventions
- Biological: GBS-NN/NN2 VaccineBiological: Placebo
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Minervax ApS
- Target Recruit Count
- 269
- Registration Number
- NCT05154578
- Locations
- 🇩🇰
Aarhus University Hospital; Skejby, Aarhus, Denmark
🇩🇰Hvidovre University Hospital, Hvidovre, Denmark
🇩🇰Institut for Regional Sundhedsforskning, Kolding, Denmark
- Prev
- 1
- 2
- Next